Crucell receives funding for its malaria vaccine technology

Saturday 1 August 2009

Crucell NV of the Netherlands said the US government has agreed to fund further clinical studies of its adenovirus-based vaccine technology against the malaria parasite, Plasmodium falciparum.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands